0000899243-18-027475.txt : 20181025 0000899243-18-027475.hdr.sgml : 20181025 20181025182435 ACCESSION NUMBER: 0000899243-18-027475 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181023 FILED AS OF DATE: 20181025 DATE AS OF CHANGE: 20181025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chimovits Erez CENTRAL INDEX KEY: 0001706399 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38707 FILM NUMBER: 181139917 MAIL ADDRESS: STREET 1: P.O. BOX 4023 CITY: HERZLIYA PITUACH STATE: L3 ZIP: 4614001 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LogicBio Therapeutics, Inc. CENTRAL INDEX KEY: 0001664106 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 471514975 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 700 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 61(0)428-338-594 MAIL ADDRESS: STREET 1: 700 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-10-23 0 0001664106 LogicBio Therapeutics, Inc. LOGC 0001706399 Chimovits Erez C/O LOGICBIO THERAPEUTICS, INC. 610 MAIN STREET, 3RD FLOOR CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2018-10-23 4 C 0 2997760 A 2997760 I See Footnote Common Stock 2018-10-23 4 P 0 490000 10.00 A 3487760 I See Footnote Series A Convertible Preferred Stock 2018-10-23 4 C 0 2678571 0.00 D Common Stock 1402444 0 I See Footnote Series B Convertible Preferred Stock 2018-10-23 4 C 0 3046943 0.00 D Common Stock 1595316 0 I See Footnote The total represents shares received upon conversion of Series A and Series B Convertible Preferred Stock. Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock. The Reporting Person is an employee of OrbiMed Advisors Israel II Limited ("OrbiMed Limited"), which is the managing member of OrbiMed Israel GP II, L.P. ("OIP GP"). OIP GP is the general partner of OrbiMed Israel Partners II, L.P. ("OIP II"), the direct beneficial owner of these securities. By virtue of such relationships, OIP GP and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest. /s/ Matthias Jaffe, as Attorney-in-Fact 2018-10-25